244 related articles for article (PubMed ID: 11830520)
1. NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes.
Georgakoudi I; Jacobson BC; Müller MG; Sheets EE; Badizadegan K; Carr-Locke DL; Crum CP; Boone CW; Dasari RR; Van Dam J; Feld MS
Cancer Res; 2002 Feb; 62(3):682-7. PubMed ID: 11830520
[TBL] [Abstract][Full Text] [Related]
2. Ultraviolet-induced autofluorescence characterization of normal and tumoral esophageal epithelium cells with quantitation of NAD(P)H.
Villette S; Pigaglio-Deshayes S; Vever-Bizet C; Validire P; Bourg-Heckly G
Photochem Photobiol Sci; 2006 May; 5(5):483-92. PubMed ID: 16685326
[TBL] [Abstract][Full Text] [Related]
3. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
4. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
5. Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history.
Goldblum JR; Lauwers GY
Semin Diagn Pathol; 2002 Feb; 19(1):12-9. PubMed ID: 11936261
[TBL] [Abstract][Full Text] [Related]
6. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
7. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
8. Nuclear translocation of glutathione transferase omega is a progression marker in Barrett's esophagus.
Piaggi S; Marchi S; Ciancia E; Debortoli N; Lazzarotti A; Saviozzi M; Raggi C; Fierabracci V; Visvikis A; Bisgaard HC; Casini AF; Paolicchi A
Oncol Rep; 2009 Feb; 21(2):283-7. PubMed ID: 19148497
[TBL] [Abstract][Full Text] [Related]
9. [Risk estimation in Barrett's esophagus: biomolecular marker and histopathologic classification].
Walch A; Schmitt-Gräff A; Stein H; Werner M
Zentralbl Chir; 2002 Dec; 127(12):1073-7. PubMed ID: 12529823
[TBL] [Abstract][Full Text] [Related]
10. Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1.
Brändlein S; Beyer I; Eck M; Bernhardt W; Hensel F; Müller-Hermelink HK; Vollmers HP
Cancer Res; 2003 May; 63(9):2052-61. PubMed ID: 12727819
[TBL] [Abstract][Full Text] [Related]
11. The combined use of fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in Barrett's esophagus.
Georgakoudi I; Feld MS
Gastrointest Endosc Clin N Am; 2004 Jul; 14(3):519-37, ix. PubMed ID: 15261200
[TBL] [Abstract][Full Text] [Related]
12. Barrett's esophagus and Barrett's-related dysplasia.
Goldblum JR
Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
[TBL] [Abstract][Full Text] [Related]
13. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
14. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
15. Temporally and spectrally resolved fluorescence spectroscopy for the detection of high grade dysplasia in Barrett's esophagus.
Pfefer TJ; Paithankar DY; Poneros JM; Schomacker KT; Nishioka NS
Lasers Surg Med; 2003; 32(1):10-6. PubMed ID: 12516065
[TBL] [Abstract][Full Text] [Related]
16. Spectroscopic detection and evaluation of morphologic and biochemical changes in early human oral carcinoma.
Müller MG; Valdez TA; Georgakoudi I; Backman V; Fuentes C; Kabani S; Laver N; Wang Z; Boone CW; Dasari RR; Shapshay SM; Feld MS
Cancer; 2003 Apr; 97(7):1681-92. PubMed ID: 12655525
[TBL] [Abstract][Full Text] [Related]
17. [Fluorescence endoscopy in gastroenterology].
Messmann H
Z Gastroenterol; 2000 Jan; 38(1):21-30. PubMed ID: 10689744
[TBL] [Abstract][Full Text] [Related]
18. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
[TBL] [Abstract][Full Text] [Related]
19. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
20. New developments in the endoscopic surveillance of Barrett's oesophagus.
Bergman JJ; Tytgat GN
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i38-42. PubMed ID: 15711007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
